SCAP Monoclonal Antibody

$Lane 1: HT-29 cell lysates; Lane 2: LNCaP cell lysates probed with SCAP Monoclonal Antibody, Unconjugated (bsm-51702M) at 1:4000 dilution and 4\u02daC overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37\u02daC.$

Lane 1: HT-29 cell lysates; Lane 2: LNCaP cell lysates probed with SCAP Monoclonal Antibody, Unconjugated (bsm-51702M) at 1:4000 dilution and 4\u02daC overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37\u02daC.

Applications

Reactivity

Human

Overview
Catalog #	bsm-51702m
Product Name	SCAP Monoclonal Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	KLH conjugated synthetic peptide derived from human SCAP
Immunogen Range	41-140/1279
Clonality	Monoclonal
Clone #	B7T5
Concentration	0.5ug/ul
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	22937
Swiss Prot	Q12770
Subcellular location	Cytoplasm, Cell membrane
Synonyms	KIAA0199; SCAP_HUMAN; SREBF chaperone; SREBF chaperone protein; SREBP cleavage activating protein; SREBP cleavage-activating protein; Sterol regulatory element binding protein cleavage-activating protein; Sterol regulatory element-binding protein cleavage-activating protein.
Background	Escort protein required for cholesterol as well as lipid homeostasis. Regulates export of the SCAP/SREBF complex from the ER upon low cholesterol. Formation of a ternary complex with INSIG at high sterol concentrations leads to masking of an ER-export signal in SCAP and retention of the complex in the ER. Low sterol concentrations trigger release of INSIG, a conformational change in the SSC domain of SCAP, unmasking of the ER export signal, recruitment into COPII-coated vesicles, transport to the Golgi complex, proteolytic cleavage of SREBF in the Golgi, release of the transcription factor fragment of SREBF from the membrane, its import into the nucleus and up-regulation of LDLR, INSIG1 and the mevalonate pathway.
Application Dilution
WB	=1:500-2000